Navigation Links
TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
Date:5/18/2009

SAN DIEGO, May 18 /PRNewswire/ -- TriLink BioTechnologies, Inc. today announced that it has signed a service agreement with Osmetech Molecular Diagnostics to supply reagents for Osmetech's recently launched eSensor(R) Cystic Fibrosis Carrier Detection (CFCD) System and the eSensor(R) XT-8 System for Warfarin Sensitivity.

As part of the agreement, TriLink is providing Osmetech with custom oligonucleotides, which are required reagents for the eSensor(R) detection systems.

"TriLink provides high quality reagents which have contributed to the excellent performance of our eSensor(R) products in the marketplace to date," said Osmetech Molecular Diagnostics COO, Pankaj Singhal.

"TriLink is proud to work with Osmetech in the advancement of this important science and rapidly developing commercial opportunity," said TriLink CEO, Dr. Richard Hogrefe.

About TriLink

TriLink Biotechnologies, Inc. manufactures custom oligonucleotides, modified nucleoside triphosphates and CleanAmp(TM) PCR products for the diagnostic and OEM markets. In addition, custom chemistry, contract research services and ISO/QSR compliant cGMP production facilities are offered. TriLink's solutions help advance drug discovery and biomedical research. Founded in 1996, TriLink is a privately held firm based in San Diego, California and employs approximately 90 scientists and other professionals. For more information about the firm and products, call 858-546-0004, email info@trilinkbiotech.com, or visit our web site at http://www.trilinkbiotech.com.

About Osmetech

Osmetech is an international diagnostics business operating in Boston and Pasadena in the US to serve the molecular diagnostic market targeting hospitals and reference laboratories. Osmetech has a strong patent portfolio and markets FDA 510(k) cleared first- and second-generation electrochemistry-based array systems, the eSensor(R) 4800 platform and the eSensor(R) XT-8 platform, presently available for Cystic Fibrosis Carrier Detection and Warfarin Sensitivity testing, respectively. The eSensor(R) XT-8 system is designed to support a broad test menu. A cytochrome P450 2C9 genotyping test (RUO) is now available while planned menu expansion includes an extended warfarin panel with the proprietary 4F2 marker, a venous thrombosis panel (Factor II, Factor V Leiden and MTHFR) and a RESPLEX(R) respiratory pathogen assay marketed in collaboration with Qiagen that is capable of detecting Swine Flu. For more information about the company and products, call (800) eSensor (373-6767), email OMDInformation@osmetech.com, or visit our web site at http://www.osmetech.com.

    Contact:
    Judy Le
    858-546-0004


'/>"/>
SOURCE TriLink BioTechnologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. TriLink Launches CleanAmp(TM) dNTPs for Hot Start PCR
2. TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project
3. Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ)
4. DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms
5. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
6. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
7. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
8. AlphaVax Announces Promising Results in Melanoma Studies
9. Tris Pharma Announces Acceptance of Its First Two NDAs
10. Bionovo Announces First Quarter 2009 Highlights and Financial Results
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
(Date:6/23/2016)... announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... ... ... Astellas is a pharmaceutical ...
(Date:6/23/2016)... 2016 The vast majority of dialysis patients ... Treatments are usually 3 times a week, with treatment ... travel time, equipment preparation and wait time.  This regimen ... for patients who are elderly and frail.  Many elderly ... rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
Breaking Medicine News(10 mins):